Neoadjuvant and Adjuvant Chemotherapy Treatment Patterns Among Older Triple-negative and HER2-positive Breast Cancer Patients with Comorbidities

被引：0
|
作者：
Tamirisa, Nina [1 ]
Dong, Wenli [1 ]
Shen, Yu [1 ]
Shaitelman, Simona [1 ]
Babiera, Gildy [1 ]
Bedrosian, Isabelle [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
ANNALS OF SURGICAL ONCOLOGY | 2023年 / 30卷 / SUPPL 2期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1387856
引用
收藏
页码：S315 / S316
页数：2
相关论文
共 50 条
  • [31] SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
    Rupert Bartsch
    memo - Magazine of European Medical Oncology, 2021, 14 : 247 - 251
  • [32] Comparison of the effectiveness of neoadjuvant chemotherapy and adjuvant chemotherapy for improving prognosis in triple-negative breast cancer patients
    Li, Wangbin
    Chang, Yuwei
    Bai, Xiaohui
    Cao, Hongxin
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2024, 16 (08): : 3978 - 3989
  • [33] Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
    Advani, Pooja
    Cornell, Lauren
    Chumsri, Saranya
    Moreno-Aspitia, Alvaro
    BREAST CANCER-TARGETS AND THERAPY, 2015, 7 : 321 - 335
  • [34] Response to neoadjuvant chemotherapy among women with triple-negative breast cancer by HER2 expression status
    Budhathoki, Pravash
    Shah, Anish
    Gaire, Suman
    Joshi, Utsav
    Yadav, Siddhartha
    CANCER RESEARCH, 2023, 83 (05)
  • [35] Adjuvant treatment for HER2-positive breast cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2015, 16 (02): : E59 - E59
  • [36] The Adjuvant Treatment of HER2-Positive Breast Cancer
    Danijela Jelovac
    Antonio C. Wolff
    Current Treatment Options in Oncology, 2012, 13 : 230 - 239
  • [37] The Adjuvant Treatment of HER2-Positive Breast Cancer
    Jelovac, Danijela
    Wolff, Antonio C.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2012, 13 (02) : 230 - 239
  • [38] Dose dense neoadjuvant and adjuvant chemotherapy in triple-negative breast cancer patients: Survival analysis
    Kr, A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [39] Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
    von Minckwitz, Gunter
    Schneeweiss, Andreas
    Loibl, Sibylle
    Salat, Christoph
    Denkert, Carsten
    Rezai, Mahdi
    Blohmer, Jens U.
    Jackisch, Christian
    Paepke, Stefan
    Gerber, Bernd
    Zahm, Dirk M.
    Kummel, Sherko
    Eidtmann, Holger
    Klare, Peter
    Huober, Jens
    Costa, Serban
    Tesch, Hans
    Hanusch, Claus
    Hilfrich, Joern
    Khandan, Fariba
    Fasching, Peter A.
    Sinn, Bruno V.
    Engels, Knut
    Mehta, Keyur
    Nekljudova, Valentina
    Untch, Michael
    LANCET ONCOLOGY, 2014, 15 (07): : 747 - 756
  • [40] Risk Factors for Ipsilateral Breast Tumor Recurrence in Triple-Negative or HER2-Positive Breast Cancer Patients Who Achieve a Pathologic Complete Response After Neoadjuvant Chemotherapy
    Ishitobi, Makoto
    Matsuda, Naoko
    Tazo, Mizuho
    Nakayama, Sayuka
    Tokui, Ryu
    Ogawa, Tomoko
    Yoshida, Atsushi
    Kojima, Yasuyuki
    Kuwayama, Takashi
    Nakayama, Takahiro
    Yamauchi, Hideko
    Nakamura, Seigo
    Tsugawa, Koichiro
    Hayashi, Naoki
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (05) : 2545 - 2552
12345